908267-36-7

Usage

Uses

Used in Pharmaceutical Synthesis:
2-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)ethanol is used as a key intermediate in the synthesis of pharmaceuticals for its unique structural features and reactivity. It contributes to the development of new drugs by providing a versatile building block that can be incorporated into various medicinal compounds.
Used in Medicinal Chemistry:
In the field of medicinal chemistry, 2-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)ethanol is utilized as a structural component in the design and synthesis of potential therapeutic agents. Its presence in a molecule can influence the pharmacokinetic and pharmacodynamic properties of the drug candidates, making it a valuable asset in the optimization of drug efficacy and safety.
Used in Organic Synthesis:
2-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)ethanol is employed as a reagent in organic synthesis for its ability to participate in a range of chemical reactions. Its versatility in forming different types of chemical bonds makes it suitable for the creation of complex organic molecules with specific properties.
Used in Materials Science:
In materials science, 2-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)ethanol may be used as a component in the development of new materials with unique properties. Its incorporation into polymers or other materials could lead to advancements in areas such as drug delivery systems, sensors, or other high-tech applications where novel materials are required.

Upstream product

• 109-84-2 2-hydroxyethylhydrazine 
• 59997-51-2 trimethylacetylacetonitrile 

Downstream Products

• 1443248-80-3 1-[5-tert-Butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-[(1S,4R)-4-(3-cyclohexyl-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy)-1,2,3,4-tetrahydro-naphthalen-1-yl]-urea 
• 1443247-49-1 1-[5-tert-butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-(2-chloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea 
• 1443247-43-5 1-[5-tert-butyl-2-(2-dimethylamino-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-(2,6-dichloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea 
• 1443248-66-5 methanesulfonic acid 2-[3-tert-butyl-5-(3-{(1S,4R)-4-[3-(2,6-dichloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-ureido)-pyrazol-1-yl]-ethyl ester 
• 1443247-40-2 1-[5-tert-butyl-2-(2-hydroxy-ethyl)-2H-pyrazol-3-yl]-3-{(1S,4R)-4-[3-(2,6-dichloro-phenyl)-[1,2,4]triazolo[4,3-a]pyridin-6-yloxy]-1,2,3,4-tetrahydro-naphthalen-1-yl}-urea 

Relevant academic research and scientific papers

UREA COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF

Provided are a urea compound represented by general formula (I), a pharmaceutically acceptable salt thereof, a preparation method therefor, and use thereof as an FLT3 tyrosine protein kinase inhibitor, particularly in the prevention and/or treating of cancer.

DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS

Mitogen activated protein kinase (MAPK) inhibitors disclosed herein are useful for the treatment of diseases of the respiratory tract, such as chronic eosinophilic pneumonia, asthma, COPD, adult respiratory distress syndrome (ARDS), exacerbation of airways hyper-reactivity consequent to other drug therapy, and airways disease that is associated with pulmonary hypertension.

DERIVATIVES OF [1, 2, 4] TRIAZOLO [4, 3 - A] PYRIDINE AS P38 - MAP KINASE INHIBITORS

This invention relates to compounds selected in the group consisting of compounds of formula (la) to (Id) and compositions, that are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

KINASE INHIBITORS

Compounds of formula (I) or a pharmaceutically acceptable salt thereof: wherein R2, W, A, Y and R1 are as defined in the specification, are p38 MAPK inhibitors, useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

KINASE INHIBITORS

Compounds of formula (I): wherein R2, W, A, Y, and R1 are as defined in the specification, and pharmaceutically acceptable salts thereof, are p38 MAPK inhibitors, and are useful as anti-inflammatory agents in the treatment of, inter alia, diseases of the respiratory tract.

PYRROLOTRIAZINE KINASE INHIBITORS

The present invention provides compounds of formula I and pharmaceutically acceptable salts thereof. The formula I compounds inhibit tyrosine kinase activity of Trk receptors such as TrkA, TrkB, TrkC or Flt-3 thereby making them useful as antiproliferative agents.

IMIDAZO (1, 2-A) PYRIDINE COMPOUNDS AS VEGF-R2 INHIBITORS

The present invention provides compounds that are inhibitors of VEGF-R2 of the formula: (I) and methods of using these compounds.